

CLINICAL PHARMACOLOGY & THERAPEUTICS

EDITOR

Marcus M. Reidenberg, MD

FOUNDING EDITOR

Walter Modell, MD

ASSOCIATE EDITORS

Arthur J. Atkinson, Jr., MD

Raymond L. Woosley, MD, PhD

ASSISTANT EDITOR

B. Robert Meyer, MD

MANAGING EDITOR

June Reidenberg

SENIOR MANUSCRIPT EDITOR

Connie Nelson

EDITORIAL BOARD

Darrell R. Abernethy, MD, PhD

Alvito P. Alvares, PhD

Matthew M. Ames, PhD

Fred Y. Aoki, MD

Daniel L. Azarnoff, MD

Leif Bertilsson, PhD

Joseph R. Bianchine, MD, PhD

Thorir D. Bjornsson, MD

Terrence F. Blaschke, MD

Saul S. Bloomfield, MD

Paula Botstein, MD

R. A. Branch, MD

D. Craig Brater, MD

Alastair Breckenridge, MSc, MD

Michael E. Brier, PhD

S. George Carruthers, MD

David M. Cocchetto, PhD

Robert J. Cody, Jr., MD

Allan H. Conney, PhD

Richard O. Davies, MD, PhD

C. Lindsay DeVane, PharmD

Colin Dollery, MB, ChB, BSc

Edward F. Domino, MD

Akio Ebihara, MD

David J. Edwards, PharmD

William E. Evans, PharmD

Alvan R. Feinstein, MD

Ross D. Feldman, MD

Marilynn C. Frederiksen, MD

Kathleen Giacomini, PhD

Milo Gibaldi, PhD

Peter Goldman, MD

Jean Gray, MD, FRCP(C)

Linda E. Gustavson, PhD

Perry V. Halushka, MD, PhD

Thomas K. Henthorn, MD

Linda A. Hershey, MD, PhD

Peter H. Hinderling, MD

Jordan L. Holtzman, MD, PhD

Aryeh Hurwitz, MD

Patrice Jaillon, MD

William J. Jusko, PhD

Anthony Kales, MD

Stanley A. Kaplan, PhD

Louis Lemberger, PhD, MD

Juan J. L. Lertora, MD, PhD

Gerhard Levy, PharmD

David T. Lowenthal, MD, PhD

Carl V. Manion, MD

Urs A. Meyer, MD

Edward B. Nelson, MD

Harold C. Neu, MD

David W. Nierenberg, MD

Alan S. Nies, MD

George D. Olsen, MD

Carl C. Peck, MD

Russell K. Portenoy, MD

William Z. Potter, MD, PhD

Jerome J. Schentag, PharmD

Edward M. Sellers, MD, PhD, FRCP(C)

Lewis B. Sheiner, MD

Daniel S. Sitar, PhD

Folke Sjöqvist, MD

Cedric M. Smith, MD

Reynold Spector, MD

Stephen P. Spielberg, MD, PhD

Donald R. Stanski, MD

John T. Sullivan, MB, ChB, FRACP

Robert Temple, MD

Elliot S. Vesell, MD

Robert E. Vestal, MD

Miles M. Weinberger, MD

Richard Weinshilboum, MD

William B. White, MD

Thomas L. Whitsett, MD

Grant R. Wilkinson, PhD

John T. Wilson, MD

Alastair J. J. Wood, MB, ChB

Tomoji Yanagita, MD, PhD

VOLUME 55, JANUARY-JUNE 1994

MOSBY—YEAR BOOK, INC., ST. LOUIS

CLINICAL PHARMACOLOGY & THERAPEUTICS

Official Publication of the
American Society for Clinical Pharmacology and Therapeutics
American Society for Pharmacology and Experimental Therapeutics

EDITORIAL ADVISORY COMMITTEE FOR THE JOURNAL

Darrell R. Abernethy, MD, PhD, Washington, D.C., Chair (ASCPT)
Neal L. Benowitz, MD, San Francisco, Calif. (ASCPT)
Eric P. Brass, MD, PhD, Beverly Hills, Calif. (ASPET)
D. Craig Brater, MD, Indianapolis, Ind. (ASPET)
Ross Feldman, MD, London, Ontario, Canada (ASPET)
Alan S. Nies, MD, Rahway, N.J. (ASCPT)

OFFICERS OF THE AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS

President: Joann L. Data, MD, PhD, Kalamazoo, Mich.
President-Elect: Arthur J. Atkinson, Jr., MD, Chicago, Ill.
Secretary-Treasurer: William B. Abrams, MD, Radnor, Penn.
Chair, Publications Committee: Eric P. Brass, MD, PhD, Beverly Hills, Calif.
Executive Director: Elaine Galasso, Norristown, Penn.

MEMBERS OF THE COUNCIL OF THE AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

President: Joel G. Hardman, PhD, Nashville, Tenn.
President-Elect: John P. Perkins, PhD, Dallas, Texas
Secretary-Treasurer: Salvatore J. Enna, PhD, Kansas City, Kan.
Chair, Board of Publications: Kenneth E. Moore, PhD, East Lansing, Mich.
Executive Officer: Kay A. Croker, Bethesda, Md.

Volume 55
Copyright © 1994 by
Mosby-Year Book, Inc.
All rights reserved
Printed in the United States of America

Index to volume 55

Author index

A

- Abemethy DR (see DePetrillo et al). 1994;55:44-9
 Agúndez JAG, Martínez C, Ladero JM, Ledesma MC, Ramos JM, Martín R, Rodríguez A, Jara C, Benítez J. Debrisoquin oxidation genotype and susceptibility to lung cancer. 1994;55:10-4
 —, —, Ledesma MC, Ladona MG, Ladero JM, Benítez J. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. 1994;55:412-7
 Alván G (see Paintaud et al). 1994;55:317-23
 Ament ME (see Buchman et al). 1994;55:277-83
 Anbe D (see Mungall et al). 1994;55:591-6
 Anderson DJ (see Greenberg et al). 1994;55:324-8
 Andrawis NS (see DePetrillo et al). 1994;55:44-9
 Andrus RO (see Greenberg et al). 1994;55:324-8
 Aoyama T, Sasaki T, Kotaki H, Sawada Y, Sudoh Y, Honda Y, Iga T. Pharmacokinetics and pharmacodynamics of (+)-three-methylphenidate enantiomer in patients with hypersomnia. 1994;55:270-6
 Atkinson AJ Jr (see Piergies et al). 1994;55:353-8
 Audet PR (see Boike et al). 1994;55:418-26
 Avorn J (see Monane et al). 1994;55:76-83

B

- Backman JT (see Olkkola et al). 1994;55:481-5
 Baird-Cox K (see Lindley et al). 1994;55:638-48
 Bardsy AH, Lillsunde P, Hiilesmaa VK, Seppälä T. Objectively measured perinatal exposure to meperidine and benzodiazepines in Finland. 1994;55:471-6
 Basci NE (see Bozkurt et al). 1994;55:399-401
 Becquemont L (see Funck-Brentano et al). 1994;55:256-69
 Belz GG (see de Mey et al). 1994;55:329-37
 Benet LZ (see Zia-Amirhosseini et al). 1994;55:21-7
 Benítez J (see Agúndez et al). 1994;55:10-4
 — (see Agúndez et al). 1994;55:412-7
 — (see Carrillo and Benítez). 1994;55:293-304
 Benowitz NL, Jacob P III. Nicotine metabolism in cigarette smokers and nonsmokers. 1994;55:85-7 (Letter reply)
 Berlin I, Rosenzweig P, Chalon S, Fuseau E, Landault C, Cesselin F, Blacker C, Puech AJ. Reduction of hyperglycemia after oral glucose load by the new α_2 -adrenergic receptor antagonist SL 84.0418 in healthy subjects. 1994;55:338-45
 Beminger E (see Paintaud et al). 1994;55:317-23
 Bigelow G (see Walsh et al). 1994;55:569-80
 Birch K (see Lindley et al). 1994;55:638-48
 Blacker C (see Berlin et al). 1994;55:338-45
 Bohn RL (see Monane et al). 1994;55:76-83
 Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE, Zariffa N, Jorkasky DK. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. 1994;55:418-26
 Bosse S (see Kharasch et al). 1994;55:434-40
 Bozkurt A, Basci NE, Isimer A, Sayal A, Kayaalp SO. Polymorphic debrisoquin metabolism in a Turkish population. 1994;55:399-401
 Branch RA (see May et al). 1994;55:492-500

- Brass EP, Hoppel CL, Hiatt WR. Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans. 1994;55:681-92
 Breimer DD (see van Steveninck et al). 1994;55:535-45
 — (see van Steveninck et al). 1994;55:546-55
 Breithaupt K (see de Mey et al). 1994;55:329-37
 Brenneisen R (see Widler et al). 1994;55:556-62
 Brier M (see Bunke et al). 1994;55:563-8
 Brøsen K (see Nielsen et al). 1994;55:518-27
 Brown AR (see Clifton et al). 1994;55:55-63
 Brown AT (see Schachtel et al). 1994;55:464-70
 Buchman AL, Jenden DJ, Moukarzel AA, Roch M, Rice KM, Chang AS, Ament ME. Choline pharmacokinetics during intermittent intravenous choline infusion in human subjects. 1994;55:277-83
 Bühl K (see Funck-Brentano et al). 1994;55:256-69
 Bunke M, Gleason JR Jr, Brier M, Sloan R. Effect of erythropoietin on renal excretion of a sodium load. 1994;55:563-8
 Busto U, Kaplan HL, Zawertailo L, Sellers EM. Pharmacologic effects and abuse liability of brexazenil, diazepam, and alprazolam in humans. 1994;55:451-63

C

- Capili H (see Schwartz et al). 1994;55:509-17
 Carrillo JA, Benítez J. Caffeine metabolism in a healthy Spanish population: N-acetyltransferase phenotype and oxidation pathways. 1994;55:293-304
 Carson SW (see Reiss et al). 1994;55:392-8
 Cesselin F (see Berlin et al). 1994;55:338-45
 Chalon S (see Berlin et al). 1994;55:338-45
 Chang AS (see Buchman et al). 1994;55:277-83
 Chattopadhyay B (see Kyerematen et al). 1994;55:84-5 (Letter)
 Chauvelot-Moachon L (see Chen et al). 1994;55:649-60
 Chen YL, Le Vraux V, Leneveu A, Dreyfus F, Sténeur A, Florentin I, De Sousa M, Giroud JP, Flouvat B, Chauvelot-Moachon L. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. 1994;55:649-60
 Chodnovskiy I (see Monane et al). 1994;55:76-83
 Cleves GS (see Schachtel et al). 1994;55:464-70
 Clifton GD, Harrison MR, Wermeling DP, Long RA, Fleck RJ, Rollieri RL, Weller S, Brown AR, Welch RM. Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects. 1994;55:55-63
 Cohen AF (see van Steveninck et al). 1994;55:535-45
 — (see van Steveninck et al). 1994;55:546-55
 Cone E (see Walsh et al). 1994;55:569-80

D

- Dannenberg AJ, Reidenberg MM. Dietary fatty acids are also drugs. 1994;55:5-9 (Commentary)
 —, —. Dietary fatty acids are also drugs (1994;55:5-9). 1994;55:255 (Correction)
 Daugherty J (see Schwartz et al). 1994;55:509-17
 deBethizy JD (see Kyerematen et al). 1994;55:84-5 (Letter)
 de Mey C, Breithaupt K, Schloos J, Neugebauer G, Palm D, Belz GG. Dose-effect and pharmacokinetic-pharmacodynamic relationships of the β_1 -adrenergic receptor blocking properties of various doses of carvedilol in healthy humans. 1994;55:329-37

den Hartigh J (see van Steveninck et al). 1994;55:535-45

— (see van Steveninck et al). 1994;55:546-55

DePetrillo PB, Abemethy DR, Wainer IW, Andrawis NS. Verapamil decreases lymphocyte protein kinase C activity in humans. 1994; 55:44-9

De Sousa M (see Chen et al). 1994;55:649-60

DiMasi JA, Seibring MA, Lasagna L. New drug development in the United States from 1963 to 1992. 1994;55:609-22 (Commentary)

Doi SAR. Pharmacodynamic optimization of warfarin therapy. 1994; 55:597-601

Domino EF (see Greenberg et al). 1994;55:324-8

— (see Kadoya et al). 1994;55:370-7

Donati F (see Varin et al). 1994;55:359-60 (Letter reply)

Dowek I (see Shupak et al). 1994;55:670-80

Dreyfus F (see Chen et al). 1994;55:649-60

E

Echizen H (see Yoshimoto et al). 1994;55:693-702

Eichelbaum M (see Funck-Brentano et al). 1994;55:256-69

Ermer JC, Hicks DR, Wheeler SC, Kraml M, Jusko WJ. Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin. 1994;55:305-16

Evans WE (see McLeod et al). 1994;55:15-20

F

Fairless A (see Boike et al). 1994;55:418-26

Faison EP (see Weber et al). 1994;55:346-52

Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous β -thalassemia. 1994;55:70-5

Fernandes D (see Fassos et al). 1994;55:70-5

Fiedler-Kelly J (see Schmith et al). 1994;55:360-2 (Letter reply)

Fisch HU (see Widler et al). 1994;55:556-62

Fleck RJ (see Clifton et al). 1994;55:55-63

Fleishaker JC (see Hulst et al). 1994;55:378-84

Florentin I (see Chen et al). 1994;55:649-60

Flouvat B (see Chen et al). 1994;55:649-60

Forbes A (see Gourlay et al). 1994;55:64-9

Forrester PL (see Mungall et al). 1994;55:591-6

Freed MI (see Boike et al). 1994;55:418-26

Funck-Brentano C, Becquemont L, Kroemer HK, Bühl K, Knebel NG, Eichelbaum M, Jaillon P. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. 1994;55:256-69

Fuseau E (see Berlin et al). 1994;55:338-45

G

Garg V, Jusko WJ. Pharmacodynamic modeling of nonsteroidal anti-inflammatory drugs: antipyretic effect of ibuprofen. 1994;55:87-8 (Letter)

Gariépy LP (see Varin et al). 1994;55:359-60 (Letter reply)

Genovese R (see Mungall et al). 1994;55:591-6

Giroud JP (see Chen et al). 1994;55:649-60

Glazer S (see Lindley et al). 1994;55:638-48

Gleason JR Jr (see Bunke et al). 1994;55:563-8

Glynn RJ (see Monane et al). 1994;55:76-83

Goldberg AI (see Weber et al). 1994;55:346-52

Gordon CR (see Shupak et al). 1994;55:670-80

Gordon YJ (see Tang-Liu et al). 1994;55:284-92

Gourlay S, Forbes A, Marriner T, Kutin J, McNeil J. A placebo-controlled study of three clonidine doses for smoking cessation. 1994;55:64-9

Gram LF (see Nielsen et al). 1994;55:518-27

Granneman GR (see Hussein et al). 1994;55:441-50

Grasela TH (see Schmith et al). 1994;55:360-2 (Letter reply)

Greenberg HS, Wemess SAS, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. 1994;55: 324-8

Grillo MA (see Keenan et al). 1994;55:581-90

Gumbiner B (see Reiss et al). 1994;55:392-8

Gurwitz JH (see Monane et al). 1994;55:76-83

Gustafsson LL (see Paintaud et al). 1994;55:317-23

H

Haas CE (see Reiss et al). 1994;55:392-8

Halushka PV. A message from the Scientific Program Committee chairperson: submission of abstracts for the 1995 annual meeting. 1994;55:702

Hansen MGJ (see Nielsen et al). 1994;55:518-27

Harrison JF (see Lindley et al). 1994;55:638-48

Harrison MR (see Clifton et al). 1994;55:55-63

Harry JD (see Hulst et al). 1994;55:378-84

Hatsukami DK (see Keenan et al). 1994;55:581-90

Hiatt WR (see Brass et al). 1994;55:681-92

Hicks DR (see Ermer et al). 1994;55:305-16

Hiilesmaa VK (see Bardy et al). 1994;55:471-6

Holt BI (see Toon et al). 1994;55:385-91

Honda Y (see Aoyama et al). 1994;55:270-6

Hoppel CL (see Brass et al). 1994;55:681-92

Hulst LK, Fleishaker JC, Peters GR, Harry JD, Wright DM, Ward P. Effect of age and gender on tirilazad pharmacokinetics in humans. 1994;55:378-84

Hussein Z, Samara E, Locke CS, Orchard MA, Ringham GL, Granneman GR. Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A_2 -receptor antagonist AA-2414 in normal subjects: population analysis. 1994;55:441-50

Hutabarat RM, Smith AL, Unadkat JD. Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells: in vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes. 1994;55:427-33

I

Idrizbegovic E (see Paintaud et al). 1994;55:317-23

Iga T (see Aoyama et al). 1994;55:270-6

Ilson BE (see Boike et al). 1994;55:418-26

Irvin JD (see Weber et al). 1994;55:346-52

Ishizaki T (see Yoshimoto et al). 1994;55:693-702

Isimer A (see Bozkurt et al). 1994;55:399-401

J

Jacob P III (see Benowitz and Jacob). 1994;55:85-7 (Letter reply)

Jaillon P (see Funck-Brentano et al). 1994;55:256-69

Jara C (see Agúndez et al). 1994;55:10-4

Jenden DJ (see Buchman et al). 1994;55:277-83

Jorkasky DK (see Boike et al). 1994;55:418-26

Jusko WJ (see Ermer et al). 1994;55:305-16

— (see Garg and Jusko). 1994;55:87-8 (Letter)

K

Kadoya C, Domino EF, Matsuoka S. Relationship of electroencephalographic and cardiovascular changes to plasma nicotine levels in tobacco smokers. 1994;55:370-7

Kalix P (see Widler et al). 1994;55:556-62

Kaplan HL (see Busto et al). 1994;55:451-63

Karki SD (see Reiss et al). 1994;55:392-8

Karlsson KK (see Paintaud et al). 1994;55:317-23

Karlsson MO, Sheiner LB. Estimating bioavailability when clearance varies with time. 1994;55:623-37

- Kayaalp SO (see Bozkurt et al). 1994;55:399-401
Keenan RM, Hataukami DK, Pentel PR, Thompson TN, Grillo MA. Pharmacodynamic effects of cotinine in abstinent cigarette smokers. 1994;55:581-90
Khan AZ (see Toon et al). 1994;55:385-91
Kharasch ED, Thummel KE, Mautz D, Bosse S. Clinical enflurane metabolism by cytochrome P450 2E1. 1994;55:434-40
Klein J (see Fassos et al). 1994;55:70-5
Klotz U (see Treiber et al). 1994;55:486-91
Knebel NG (see Funck-Brentano et al). 1994;55:256-69
Kondo T (see Yoshimoto et al). 1994;55:693-702
Konerman JP (see Schachtel et al). 1994;55:464-70
Koren G (see Fassos et al). 1994;55:70-5
Kotaki H (see Aoyama et al). 1994;55:270-6
Kraml M (see Ermer et al). 1994;55:305-16
Kroemer HK (see Funck-Brentano et al). 1994;55:256-69
Kutin J (see Gourlay et al). 1994;55:64-9
Kyerematen GA, Morgan ML, Chattopadhyay B, deBethizy JD, Vesell ES. Nicotine metabolism in cigarette smokers and nonsmokers. 1994;55:84-5 (Letter)

L

- Ladero JM (see Agúndez et al). 1994;55:10-4
— (see Agúndez et al). 1994;55:412-7
Ladona MG (see Agúndez et al). 1994;55:412-7
Landault C (see Berlin et al). 1994;55:338-45
Langley SJ (see Toon et al). 1994;55:385-91
Lasagna L (see DiMasi et al). 1994;55:609-22 (Commentary)
Laskin OL (see Schwartz et al). 1994;55:50-4
Lasseter KC (see Schwartz et al). 1994;55:50-4
LeBlanc S (see Mungall et al). 1994;55:591-6
Ledesma MC (see Agúndez et al). 1994;55:10-4
— (see Agúndez et al). 1994;55:412-7
Leenen FH (see Shaw-Stiffel et al). 1994;55:661-9
Leneveu A (see Chen et al). 1994;55:649-60
Le Vraux V (see Chen et al). 1994;55:649-60
Levy G. Effect of advanced age on the pharmacodynamics of doxacurium. 1994;55:359 (Letter)
Lillsunde P (see Bardy et al). 1994;55:471-6
Lin JS (see McLeod et al). 1994;55:15-20
Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. 1994;55:638-48
Lipschutz K (see Weber et al). 1994;55:346-52
Locke CS (see Hussein et al). 1994;55:441-50
Long RA (see Clifton et al). 1994;55:55-63
Luoma T (see Mungall et al). 1994;55:591-6
Lusher J (see Lindley et al). 1994;55:638-48

M

- Macik BG (see Lindley et al). 1994;55:638-48
Mahan J (see Mungall et al). 1994;55:591-6
Markham AO (see Schachtel et al). 1994;55:464-70
Mariner T (see Gourlay et al). 1994;55:64-9
Martín R (see Agúndez et al). 1994;55:10-4
Martínez C (see Agúndez et al). 1994;55:10-4
— (see Agúndez et al). 1994;55:412-7
Mathys K (see Widler et al). 1994;55:556-62
Matsui D (see Fassos et al). 1994;55:70-5
Matsuoka S (see Kadoya et al). 1994;55:370-7
Mautz D (see Kharasch et al). 1994;55:434-40
May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. 1994;55:492-500
McDonagh AF (see Zia-Amirhosseini et al). 1994;55:21-7

- McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. 1994;55:15-20
McMahon FG. Subcommittee report from the Government Affairs Committee. 1994;55:363
McNamara S (see Wang et al). 1994;55:528-34
McNeil J (see Gourlay et al). 1994;55:64-9
Meeter CA (see Schwartz et al). 1994;55:50-4
Miners JO (see Stockley et al). 1994;55:35-43
Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Chodnovskiy I, Avorn J. Topical glaucoma medications and cardiovascular risk in the elderly. 1994;55:76-83
Morgan ML (see Kyerematen et al). 1994;55:84-5 (Letter)
Mörke KE, Roden DM. Quinidine-enhanced β -blockade during treatment with propafenone in extensive metabolizer human subjects. 1994;55:28-34
Moukartzel AA (see Buchman et al). 1994;55:277-83
Mullins FGP (see Toon et al). 1994;55:385-91
Mungall DR, Anbe D, Forrester PL, Luoma T, Genovese R, Mahan J, LeBlanc S, Penney JB. A prospective randomized comparison of the accuracy of computer-assisted versus GUSTO nomogram-directed heparin therapy. 1994;55:591-6

N

- Nakamura Y (see Yoshimoto et al). 1994;55:693-702
Nelson EB (see Weber et al). 1994;55:346-52
Neugebauer G (see de Mey et al). 1994;55:329-37
Neuvonen PJ (see Olkkola et al). 1994;55:481-5
Nielsen KK, Brøsen K, Hansen MG, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. 1994;55:118-27
Nierenberg DW. A message from the President: come to New Orleans, March 30 - April 1, 1994. 1994;55:92
—, Reidenberg MM. Criteria for judging proposals for national health care reform with respect to therapeutics. 1994;55:1-4 (Commentary)

O

- Ogilvie RI (see Shaw-Stiffel et al). 1994;55:661-9
Ojingwa JC (see Zia-Amirhosseini et al). 1994;55:21-7
Olivieri NF (see Fassos et al). 1994;55:70-5
Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. 1994;55:481-5
Orchard MA (see Hussein et al). 1994;55:441-50
O'Sullivan TA (see Wang et al). 1994;55:528-34

P

- Paintaud G, Alván G, Berninger E, Gustafsson LL, Idrizbegovic E, Karlsson KK, Wakelkamp M. The concentration-effect relationship of quinine-induced hearing impairment. 1994;55:317-23
Palm D (see de Mey et al). 1994;55:329-37
Patterson PM (see Schwartz et al). 1994;55:50-4
Penney JB (see Mungall et al). 1994;55:591-6
Pentel PR (see Keenan et al). 1994;55:581-90
Peters GR (see Hulst et al). 1994;55:378-84
Piergies AA, Worwag E, Atkinson AJ Jr. A concurrent audit of high digoxin plasma levels. 1994;55:353-8
Pieters MSM (see van Steveninck et al). 1994;55:535-45
— (see van Steveninck et al). 1994;55:546-55
Portenoy RK (see Reidenberg and Portenoy). 1994;55:367-9 (Commentary)
Porter J (see May et al). 1994;55:492-500
Preston K (see Walsh et al). 1994;55:569-80
Priest DG (see Schmitz et al). 1994;55:501-8
Pue MA (see Boike et al). 1994;55:418-26

- Puech AJ (see Berlin et al). 1994;55:338-45
 Pugh JE (see Greenberg et al). 1994;55:324-8
 Pui CH (see McLeod et al). 1994;55:15-20

R

- Ramos JM (see Agúndez et al). 1994;55:10-4
 Ramsey B (see Wang et al). 1994;55:528-34
 Reidenberg MM. The Pinocchio factor. 1994;55:247-8 (Commentary)
 —, Portenoy RK. The need for an open mind about the treatment of chronic nonmalignant pain. 1994;55:367-9 (Commentary)
 — (see Dannenberg and Reidenberg). 1994;55:5-9 (Commentary)
 — (see Nierenberg and Reidenberg). 1994;55:1-4 (Commentary)
 Reiss RA, Haas CE, Karki SD, Gumbiner B, Welle SL, Carson SW. Lithium pharmacokinetics in the obese. 1994;55:392-8
 Rice KM (see Buchman et al). 1994;55:277-83
 Rijnkels J (see van Steveninck et al). 1994;55:535-45
 Ringham GL (see Hussein et al). 1994;55:441-50
 Roberts HR (see Lindley et al). 1994;55:638-48
 Roch M (see Buchman et al). 1994;55:277-83
 Roden DM (see Mörike and Roden). 1994;55:28-34
 Rodriguez A (see Agúndez et al). 1994;55:10-4
 Roller RL (see Clifton et al). 1994;55:55-63
 Roots I (see Rost and Roots). 1994;55:402-11
 Rosenzweig P (see Berlin et al). 1994;55:338-45
 Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolic ratios: coincidence with plasma clearance and breath test. 1994;55:402-11
 Rowland MM (see Toon et al). 1994;55:385-91

S

- Saima S (see Yoshimoto et al). 1994;55:693-702
 Samara E (see Hussein et al). 1994;55:441-50
 Sasaki T (see Aoyama et al). 1994;55:270-6
 Sawada Y (see Aoyama et al). 1994;55:270-6
 Sawyer WT (see Lindley et al). 1994;55:638-48
 Sayal A (see Bozkurt et al). 1994;55:399-401
 Schachtel BP, Cleves GS, Konerman JP, Brown AT, Markham AO. A placebo-controlled model to assay the onset of action of nonprescription-strength analgesic drugs. 1994;55:464-70
 Schloos J (see de Mey et al). 1994;55:329-37
 Schmith VD, Fiedler-Kelly J, Grasele TH. Effect of advanced age on the pharmacodynamics of doxacurium. 1994;55:360-2 (Letter reply)
 Schmitz JC, Stuart RK, Priest DG. Disposition of folic acid and its metabolites: a comparison with leucovorin. 1994;55:501-8
 Schneider SH (see Schwartz et al). 1994;55:50-4
 Schoemaker HC (see van Steveninck et al). 1994;55:535-45
 — (see van Steveninck et al). 1994;55:546-55
 Schwartz JB, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. 1994;55:509-17
 Schwartz JJ, Laskin OL, Meeter CA, Patterson PM, Schneider SH, Lasseter KC, Seibold JR. Pharmacodynamics of MK-0963, a new 5 α -reductase inhibitor: effects on serum androgen concentrations. 1994;55:50-4
 Schwob DL (see Tang-Liu et al). 1994;55:284-92
 Scott EP (see McLeod et al). 1994;55:15-20
 Seibold JR (see Schwartz et al). 1994;55:50-4
 Seibring MA (see DiMasi et al). 1994;55:609-22 (Commentary)
 Sellers EM (see Busto et al). 1994;55:451-63
 Seppälä T (see Bardy et al). 1994;55:471-6
 Shapiro DA (see Weber et al). 1994;55:346-52
 Shaw-Stiffel TA, Walker SE, Ogilvie RI, Leenen FH. Pharmacokinetic and pharmacodynamic interactions during multiple-dose administration of nisoldipine and propranolol. 1994;55:661-9
 Sheiner LB (see Karlsson and Sheiner). 1994;55:623-37

- Shupak A, Doweck I, Gordon CR, Spitzer O. Cinnarizine in the prophylaxis of seasickness: laboratory vestibular evaluation and sea study. 1994;55:670-80
 Sloan R (see Bunke et al). 1994;55:563-8
 Smith AL (see Hutabarat et al). 1994;55:427-33
 — (see Wang et al). 1994;55:528-34
 Spahn-Langguth H (see Zia-Amirhosseini et al). 1994;55:21-7
 Spitzer O (see Shupak et al). 1994;55:670-80
 Stheneur A (see Chen et al). 1994;55:649-60
 Stitzer M (see Walsh et al). 1994;55:569-80
 Stockley CS, Wing LMH, Tonkin AL, Miners JO. Dispositional factors do not contribute to the enantiospecificity of the cardiovascular effects of phenylpropanolamine. 1994;55:35-43
 Stuart RK (see Schmitz et al). 1994;55:501-8
 Sudoh Y (see Aoyama et al). 1994;55:270-6

T

- Tang-Liu DDS, Schwob DL, Usansky JJ, Gordon YJ. Comparative tear concentrations over time of ofloxacin and tobramycin in human eyes. 1994;55:284-92
 Thompson TN (see Keenan et al). 1994;55:581-90
 Thummel KE (see Kharasch et al). 1994;55:434-40
 Tonkin AL (see Stockley et al). 1994;55:35-43
 Toon S, Khan AZ, Holt BI, Mullins FGP, Langley SJ, Rowland MM. Absence of effect of ranitidine on blood alcohol concentrations when taken morning, midday, or evening with or without food. 1994;55:385-91
 Trager WF (see Wang et al). 1994;55:528-34
 Treiber G, Walker S, Klotz U. Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrate bismuthate. 1994;55:486-91

U

- Unadkat JD (see Hutabarat et al). 1994;55:427-33
 — (see Wang et al). 1994;55:528-34
 Usansky JJ (see Tang-Liu et al). 1994;55:284-92

V

- van Steveninck AL, Schoemaker HC, den Hartigh J, Pieters MSM, Breimer DD, Cohen AF. Effects of intravenous temazepam. II. A study of the long-term reproducibility of pharmacokinetics, pharmacodynamics, and concentration-effect parameters. 1994;55:546-55
 —, —, —, Rijnkels J, Pieters MSM, Breimer DD, Cohen AF. Effects of intravenous temazepam. I. Saccadic eye movements and electroencephalogram after fast and slow infusion to pseudo steady state. 1994;55:535-45
 Varin F, Gariépy LP, Donati F. Effect of advanced age on the pharmacodynamics of doxacurium. 1994;55:359-60 (Letter reply)
 Vesell ES (see Kyerematen et al). 1994;55:84-5 (Letter)

W

- Wainer IW (see DePetrillo et al). 1994;55:44-9
 Wakelkamp M (see Paintaud et al). 1994;55:317-23
 Walker S (see Treiber et al). 1994;55:486-91
 Walker SE (see Shaw-Stiffel et al). 1994;55:661-9
 Walsh S, Preston K, Stitzer M, Cone E, Bigelow G. Clinical pharmacology of buprenorphine: ceiling effects at high doses. 1994;55:569-80
 Wang JP, Unadkat JD, McNamara S, O'Sullivan TA, Smith AL, Trager WF, Ramsey B. Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis. 1994;55:528-34
 Ward P (see Hulst et al). 1994;55:378-84

- Weber MA, Goldberg AI, Faison EP, Lipschutz K, Shapiro DA, Nelson EB, Irvin JD. Extended-release felodipine in patients with mild to moderate hypertension. 1994;55:346-52
- Welch RM (*see* Clifton et al). 1994;55:55-63
- Welle SL (*see* Reiss et al). 1994;55:392-8
- Weller S (*see* Clifton et al). 1994;55:55-63
- Wermeling DP (*see* Clifton et al). 1994;55:55-63
- Werness SAS (*see* Greenberg et al). 1994;55:324-8
- Wheeler SC (*see* Ermer et al). 1994;55:305-16
- Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU. Pharmacodynamics and pharmacokinetics of khat: a controlled study. 1994;55:556-62
- Wilkinson GR (*see* May et al). 1994;55:492-500
- Wing LMH (*see* Stockley et al). 1994;55:35-43
- Woosley RL. Centers for Education and Research in Therapeutics. 1994;55:249-55 (Commentary)
- Worwag E (*see* Piergies et al). 1994;55:353-8

- Wright DM (*see* Hulst et al). 1994;55:378-84

Y

- Yagishita Y (*see* Yoshimoto et al). 1994;55:693-702
- Yoshimoto K, Saima S, Echizen H, Nakamura Y, Kondo T, Yagishita Y, Ishizaki T. Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure. 1994;55:693-702

Z

- Zariffa N (*see* Boike et al). 1994;55:418-26
- Zawertailo L (*see* Busto et al). 1994;55:451-63
- Zia-Amirhosseini P, Ojingwa JC, Spahn-Langguth H, McDonagh AF, Benet LZ. Enhanced covalent binding of tolmetin to proteins in humans after multiple dosing. 1994;55:21-7

Subject index

A

Absorption

Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate (Treiber et al). 1994;55:486-91

Acetylation

Caffeine metabolism in a healthy Spanish population: *N*-acetylator phenotype and oxidation pathways (Carrillo and Benítez). 1994;55:293-304

Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells: in vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes (Hutabarat et al). 1994;55:427-33

Acute phase response

Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics (Chen et al). 1994;55:649-60

Adatanserin hydrochloride

Adatanserin hydrochloride (USAN List No. 358). 1994;55:366

Administration, topical

Comparative tear concentrations over time of ofloxacin and tobramycin in human eyes (Tang-Liu et al). 1994;55:284-92

Topical glaucoma medications and cardiovascular risk in the elderly (Monane et al). 1994;55:76-83

Adrenergic alpha receptor agonists

Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A₂-receptor antagonist AA-2414 in normal subjects: population analysis (Hussein et al). 1994;55:441-50

Adrenergic alpha receptor blockers

Reduction of hyperglycemia after oral glucose load by the new α_2 -adrenergic receptor antagonist SL 84.0418 in healthy subjects (Berlin et al). 1994;55:338-45

Adrenergic beta receptor blockers

Dose-effect and pharmacokinetic-pharmacodynamic relationships of the β_1 -adrenergic receptor blocking properties of various doses of carvedilol in healthy humans (de Mey et al). 1994;55:329-37

Quinidine-enhanced β -blockade during treatment with propafenone in extensive metabolizer human subjects (Mörke and Roden). 1994;55:28-34

Age factors

Effect of advanced age on the pharmacodynamics of doxacurium (Levy) (Letter); (Varin et al) (Reply). 1994;55:359-60

Effect of age and gender on tirilazad pharmacokinetics in humans (Hulst et al). 1994;55:378-84

Aged

Topical glaucoma medications and cardiovascular risk in the elderly (Monane et al). 1994;55:76-83

Aging

Aging of women alters *S*-verapamil pharmacokinetics and pharmacodynamics (Schwartz et al). 1994;55:509-17

January, pp. 1-122; February, pp. 123-246; March, pp. 247-366; April, pp. 367-480; May, 481-608; June, 609-718.

Alcohol drinking

Absence of effect of ranitidine on blood alcohol concentrations when taken morning, midday, or evening with or without food (Toon et al). 1994;55:385-91

Alprazolam

Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans (Busto et al). 1994;55:451-63

Alvircept sudotox

Alvircept sudotox (USAN List No. 357). 1994;55:90

American Society for Clinical Pharmacology and Therapeutics

Election of officers and committee chairpersons for 1994-1995. 1994;55:701-2

A message from the Membership Committee Chairman. 1994;55:602

A message from the President: come to New Orleans, March 30 - April 1, 1994 (Nierenberg). 1994;55:92

A message from the Scientific Program Committee chairperson: submission of abstracts for the 1995 annual meeting (Halushka). 1994;55:702

New members of the Society. 1994;55:602-5

Program of the Ninety-fifth Annual Meeting. 1994;55:93-122

Subcommittee report from the Government Affairs Committee (McMahon). 1994;55:363

Amlodarone

Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amlodarone (Funck-Brentano et al). 1994;55:256-69

Analgesics

A placebo-controlled model to assay the onset of action of nonprescription-strength analgesic drugs (Schachtel et al). 1994;55:464-70

Androgens

Pharmacodynamics of MK-0963, a new 5 α -reductase inhibitor: effects on serum androgen concentrations (Schwartz et al). 1994;55:50-4

Anti-inflammatory agents, non-steroidal

Enhanced covalent binding of tolmetin to proteins in humans after multiple dosing (Zia-Amirhosseini et al). 1994;55:21-7

Arachidonic acid

Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A₂-receptor antagonist AA-2414 in normal subjects: population analysis (Hussein et al). 1994;55:441-50

B

Benzodiazepines

Objectively measured perinatal exposure to meperidine and benzodiazepines in Finland (Bardy et al). 1994;55:471-6

Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans (Busto et al). 1994;55:451-63

Beta-blockade; see Adrenergic beta receptor blockers

Biological availability

Estimating bioavailability when clearance varies with time (Karlsson and Sheiner). 1994;55:623-37

Bismuth

Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate (Treiber et al). 1994;55:486-91

Blood glucose

Reduction of hyperglycemia after oral glucose load by the new α_2 -adrenergic receptor antagonist SL 84.0418 in healthy subjects (Berlin et al). 1994;55:338-45

Blood pressure

Pharmacodynamics and pharmacokinetics of khat: a controlled study (Widler et al). 1994;55:556-62
Relationship of electroencephalographic and cardiovascular changes to plasma nicotine levels in tobacco smokers (Kadoya et al). 1994;55:370-7

Breath tests

Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolic ratios: coincidence with plasma clearance and breath test (Rost and Roots). 1994;55:402-11

Bretazenil

Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans (Busto et al). 1994;55:451-63

Buprenorphine

Clinical pharmacology of buprenorphine: ceiling effects at high doses (Walsh et al). 1994;55:569-80

C

Caffeine

Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolic ratios: coincidence with plasma clearance and breath test (Rost and Roots). 1994;55:402-11
Caffeine metabolism in a healthy Spanish population: *N*-acetylator phenotype and oxidation pathways (Carrillo and Benitez). 1994;55:293-304

Cardiotonic agents

Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects (Clifton et al). 1994;55:55-63

Cardiovascular effects; see Hemodynamics

Carnitine

Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans (Brass et al). 1994;55:681-92

Carvedilol

Dose-effect and pharmacokinetic-pharmacodynamic relationships of the β_1 -adrenergic receptor blocking properties of various doses of carvedilol in healthy humans (de Mey et al). 1994;55:329-37

Centers for Education and Research in Therapeutics

Centers for Education and Research in Therapeutics (Woosley). 1994;55:249-55 (Commentary)

Central nervous system

Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure (Yoshimoto et al). 1994;55:693-702

Cerebrospinal fluid

Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure (Yoshimoto et al). 1994;55:693-702

Choline

Choline pharmacokinetics during intermittent intravenous choline infusion in human subjects (Buchman et al). 1994;55:277-83

Cigarette smokers; see Smoking

Cinnarizine

Cinnarizine in the prophylaxis of seasickness: laboratory vestibular evaluation and sea study (Shupak et al). 1994;55:670-80

Clomipramine

Single-dose kinetics of clomipramine: relationship to the sparteine and *S*-mephenytoin oxidation polymorphisms (Nielsen et al). 1994;55:518-27

Clonidine

A placebo-controlled study of three clonidine doses for smoking cessation (Gourlay et al). 1994;55:64-9

Commentaries

Commentaries. 1994;55:1-9, 247-55, 367-9, 609-22

Computer-assisted drug therapy; see Drug therapy, computer-assisted

Corrections

Dietary fatty acids are also drugs (Dannenberg and Reidenberg). 1994;55:5-9. 1994;55:255
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and *S*-mephenytoin (Bertilsson et al) (1992;51:388-97). 1994;55:648

Correspondence; see Letters

Corticotropin ovine trifluoracetate

Corticotropin ovine trifluoracetate (USAN List No. 357). 1994;55:91

Cotinine

Pharmacodynamic effects of cotinine in abstinent cigarette smokers (Keenan et al). 1994;55:70-2

Cyclosporine

Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics (Chen et al). 1994;55:649-60

Cystic fibrosis

Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (*R*)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis (Wang et al). 1994;55:528-34
Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells: in vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes (Hutabarat et al). 1994;55:427-33

Cytochrome P450

Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics (Chen et al). 1994;55:649-60
Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (*R*)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis (Wang et al). 1994;55:528-34

Cytochromes

Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolic ratios: coincidence with plasma clearance and breath test (Rost and Roots). 1994;55:402-11
Clinical enflurane metabolism by cytochrome P450 2E1 (Kharasch et al). 1994;55:434-40
Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations (Agúndez et al). 1994;55:412-7

D

Dapsone

Frequency distribution of dapsone *N*-hydroxylase, a putative probe for P4503A4 activity, in a white population (May et al). 1994;55:492-500

Debrisoquin

Debrisoquin oxidation genotype and susceptibility to lung cancer (Agúndez et al). 1994;55:10-4
Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations (Agúndez et al). 1994;55:412-7
Polymorphic debrisoquin metabolism in a Turkish population (Bozkurt et al). 1994;55:399-401

Diazepam

Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans (Busto et al). 1994;55:451-63

Diet

Dietary fatty acids are also drugs (Dannenberg and Reidenberg). 1994;55:5-9 (Commentary)

Diglitoxin

A concurrent audit of high digoxin plasma levels (Piergies et al). 1994;55:353-8

Digoxin

A concurrent audit of high digoxin plasma levels (Piergies et al). 1994;55:353-8

1,2-Dimethyl-3-hydroxypyrid-4-one

Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous β -thalassemia (Fassos et al). 1994;55:70-5

Dofetilide

Dofetilide (USAN List No. 359). 1994;55:480

Dose-response relationship, drug

Clinical pharmacology of buprenorphine: ceiling effects at high doses (Walsh et al). 1994;55:569-80

Pharmacodynamic optimization of warfarin therapy (Doi). 1994;55:597-601

A prospective randomized comparison of the accuracy of computer-assisted versus GUSTO nomogram-directed heparin therapy (Mungall et al). 1994;55:591-6

Doxacurium

Effect of advanced age on the pharmacodynamics of doxacurium (Levy) (Letter); (Varin et al) (Reply). 1994;55:359-60

Draflazine

Draflazine (USAN List No. 359). 1994;55:478

Drug clearance

Estimating bioavailability when clearance varies with time (Karlsson and Sheiner). 1994;55:623-37

Drug development

New drug development in the United States from 1963 to 1992 (DiMasi et al). 1994;55:609-22 (Commentary)

Drug evaluation

Disposition of folic acid and its metabolites: a comparison with leucovorin (Schmitz et al). 1994;55:501-8

Drug industry

Criteria for judging proposals for national health care reform with respect to therapeutics (Nierenberg and Reidenberg). 1994;55:1-4 (Commentary)

New drug development in the United States from 1963 to 1992 (DiMasi et al). 1994;55:609-22 (Commentary)

Drug interactions

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole (Olkola et al). 1994;55:481-5

Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrate bismuthate (Treiber et al). 1994;55:486-91

Pharmacokinetic and pharmacodynamic interactions during multiple-dose administration of nisoldipine and propranolol (Shaw-Stiffel et al). 1994;55:661-9

Drug therapy, computer-assisted

A prospective randomized comparison of the accuracy of computer-assisted versus GUSTO nomogram-directed heparin therapy (Mungall et al). 1994;55:591-6

E**Elderly; see Aged****Electrocardiography**

Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone (Funck-Brentano et al). 1994;55:256-69

Electroencephalography

Effects of intravenous temazepam. I. Saccadic eye movements and electroencephalogram after fast and slow infusion to pseudo steady state (van Steveninck et al). 1994;55:535-45

Relationship of electroencephalographic and cardiovascular changes to plasma nicotine levels in tobacco smokers (Kadoya et al). 1994;55:370-7

Enantiomers

Dispositional factors do not contribute to the enantiospecificity of the cardiovascular effects of phenylpropanolamine (Stockley et al). 1994;55:35-43

Enflurane

Clinical enflurane metabolism by cytochrome P450 2E1 (Kharasch et al). 1994;55:434-40

Erythropoietin

Effect of erythropoietin on renal excretion of a sodium load (Bunke et al). 1994;55:563-8

Etiololac

Concomitant etiololac affects neither the unbound clearance nor the pharmacologic effect of warfarin (Ermer et al). 1994;55:305-16

Exercise

Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans (Brass et al). 1994;55:681-92

Eye infections

Comparative tear concentrations over time of ofloxacin and tobramycin in human eyes (Tang-Liu et al). 1994;55:284-92

Eye movements

Effects of intravenous temazepam. I. Saccadic eye movements and electroencephalogram after fast and slow infusion to pseudo steady state (van Steveninck et al). 1994;55:535-45

F**Factor VIIa**

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa (Lindley et al). 1994;55:638-48

Famciclovir

Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment (Boike et al). 1994;55:418-26

Famotidine

Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure (Yoshimoto et al). 1994;55:693-702

Fatty acids

Dietary fatty acids are also drugs (Dannenberg and Reidenberg). 1994;55:5-9 (Commentary)

Felodipine

Extended-release felodipine in patients with mild to moderate hypertension (Weber et al). 1994;55:346-52

5 α -reductase inhibitors

Pharmacodynamics of MK-0963, a new 5 α -reductase inhibitor: effects on serum androgen concentrations (Schwartz et al). 1994;55:50-4

Flecainide

Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone (Funck-Brentano et al). 1994;55:256-69

Folic acid

Disposition of folic acid and its metabolites: a comparison with leucovorin (Schmitz et al). 1994;55:501-8

G**Gadobenate dimeglumine**

Gadobenate dimeglumine (USAN List No. 361). 1994;55:704

Gadodiamide

Gadodiamide (USAN List No. 357). 1994;55:89

Gender; see Sex

Genes, recessive

Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations (Agúndez et al). 1994;55:412-7

Genotype

Debrisoquin oxidation genotype and susceptibility to lung cancer (Agúndez et al). 1994;55:10-4

Glaucoma

Topical glaucoma medications and cardiovascular risk in the elderly (Monane et al). 1994;55:76-83

H

Health care costs

Centers for Education and Research in Therapeutics (Woosley). 1994;55:249-55 (Commentary)

Health care reform

Criteria for judging proposals for national health care reform with respect to therapeutics (Nierenberg and Reidenberg). 1994;55:1-4 (Commentary)

Hearing disorders

The concentration-effect relationship of quinine-induced hearing impairment (Painaud et al). 1994;55:317-23

Heart

Pharmacodynamics and pharmacokinetics of khat: a controlled study (Widler et al). 1994;55:556-62

Topical glaucoma medications and cardiovascular risk in the elderly (Monane et al). 1994;55:76-83

Hemodynamics

Dispositional factors do not contribute to the enantiospecificity of the cardiovascular effects of phenylpropanolamine (Stockley et al). 1994;55:35-43

Hemophilia

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa (Lindley et al). 1994;55:638-48

Heparin

A prospective randomized comparison of the accuracy of computer-assisted versus GUSTO nomogram-directed heparin therapy (Mungall et al). 1994;55:591-6

Hydroxylases

Frequency distribution of dapsone *N*-hydroxylase, a putative probe for P4503A4 activity, in a white population (May et al). 1994;55:492-500

Hyperglycemia

Reduction of hyperglycemia after oral glucose load by the new α_2 -adrenergic receptor antagonist SL 84.0418 in healthy subjects (Berlin et al). 1994;55:338-45

Hypersomnia

Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia (Aoyama et al). 1994;55:270-6

Hypertension

Extended-release felodipine in patients with mild to moderate hypertension (Weber et al). 1994;55:346-52

I

Iloperidone

Iloperidone (USAN List No. 360). 1994;55:608

Infusions, intravenous

Effects of intravenous temazepam. I. Saccadic eye movements and electroencephalogram after fast and slow infusion to pseudo steady state (van Steveninck et al). 1994;55:535-45

Effects of intravenous temazepam. II. A study of the long-term reproducibility of pharmacokinetics, pharmacodynamics, and concentration-effect parameters (van Steveninck et al). 1994;55:546-55

Interferon beta-1a

Interferon beta-1a (USAN List No. 359). 1994;55:479

Interleukin-6

Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics (Chen et al). 1994;55:649-60

Intravenous infusions; see Infusions, intravenous

Iron

Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous β -thalassemia (Fassos et al). 1994;55:70-5

Isoforms, cytochrome P450; see Cytochrome P450

Itraconazole

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole (Olkola et al). 1994;55:481-5

K

Ketoconazole

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole (Olkola et al). 1994;55:481-5

Khat

Pharmacodynamics and pharmacokinetics of khat: a controlled study (Widler et al). 1994;55:556-62

Kidney

Effect of erythropoietin on renal excretion of a sodium load (Bunke et al). 1994;55:563-8

Kidney failure

Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure (Yoshimoto et al). 1994;55:693-702
Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment (Boike et al). 1994;55:418-26

L

Labor

Objectively measured perinatal exposure to meperidine and benzodiazepines in Finland (Bardy et al). 1994;55:471-6

Lecithins; see Phosphatidylcholines

Letrozole

Letrozole (USAN List No. 359). 1994;55:478

Letters

Effect of advanced age on the pharmacodynamics of doxacurium (Levy) (Letter); (Varin et al) (Reply); (Schmith et al) (Reply). 1994;55:359-62

Nicotine metabolism in cigarette smokers and nonsmokers (Kyerematen et al) (Letter); (Benowitz and Jacob) (Reply). 1994;55:84-7

Pharmacodynamic modeling of nonsteroidal anti-inflammatory drugs: antipyretic effect of ibuprofen (Garg and Jusko). 1994;55:87-8

Leucovorin

Disposition of folic acid and its metabolites: a comparison with leucovorin (Schmitz et al). 1994;55:501-8

Liarozole fumarate

Liarozole fumarate (USAN List No. 360). 1994;55:607

Liarozole hydrochloride

Liarozole hydrochloride (USAN List No. 360). 1994;55:606

Lithium

Lithium pharmacokinetics in the obese (Reiss et al). 1994;55:392-8

Lung neoplasms

Debrisoquin oxidation genotype and susceptibility to lung cancer (Agúndez et al). 1994;55:10-4

Lurosetron mesylate

Lurosetron mesylate (USAN List No. 359). 1994;55:480

Lymphocytes

Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells: in vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes (Hutabarat et al). 1994;55:427-33

Verapamil decreases lymphocyte protein kinase C activity in humans (DePetrillo et al). 1994;55:44-9

M**Marijuana smoking**

Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers (Greenberg et al). 1994;55:324-8

Meperidine

Objectively measured perinatal exposure to meperidine and benzodiazepines in Finland (Bardy et al). 1994;55:471-6

Mephenytoin

Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms (Nielsen et al). 1994;55:518-27

Mesylates

Effect of age and gender on tirilazad pharmacokinetics in humans (Hulst et al). 1994;55:378-84

Methadone

Clinical pharmacology of buprenorphine: ceiling effects at high doses (Walsh et al). 1994;55:569-80

Methylphenidate

Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia (Aoyama et al). 1994;55:270-6

Midazolam

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole (Olkola et al). 1994;55:481-5

Mipafilcon A

Mipafilcon A (USAN List No. 361). 1994;55:704

Mitindomide

Mitindomide (USAN List No. 360). 1994;55:608

MK-0963

Pharmacodynamics of MK-0963, a new 5 α -reductase inhibitor: effects on serum androgen concentrations (Schwartz et al). 1994;55:50-4

Motion sickness

Cinnarizine in the prophylaxis of seasickness: laboratory vestibular evaluation and sea study (Shupak et al). 1994;55:670-80

Multiple sclerosis

Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers (Greenberg et al). 1994;55:324-8

Muscle spasticity

Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers (Greenberg et al). 1994;55:324-8

Muscles

Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans (Brass et al). 1994;55:681-92

N**Naratriptan hydrochloride**

Naratriptan hydrochloride (USAN List No. 359). 1994;55:480

Narcotics

Objectively measured perinatal exposure to meperidine and benzodiazepines in Finland (Bardy et al). 1994;55:471-6

New chemical entities

New drug development in the United States from 1963 to 1992 (DiMasi et al). 1994;55:609-22 (Commentary)

Nicotine

Pharmacodynamic effects of cotinine in abstinent cigarette smokers (Keenan et al). 1994;55:581-90

Relationship of electroencephalographic and cardiovascular changes to plasma nicotine levels in tobacco smokers (Kadota et al). 1994;55:370-7

Nisoldipine

Pharmacokinetic and pharmacodynamic interactions during multiple-dose administration of nisoldipine and propranolol (Shaw-Stiffel et al). 1994;55:661-9

Non-steroidal anti-inflammatory agents; see Anti-inflammatory agents, non-steroidal

O**Obesity**

Lithium pharmacokinetics in the obese (Reiss et al). 1994;55:392-8

Ocaperidone

Ocaperidone (USAN List No. 360). 1994;55:606

Ofloxacin

Comparative tear concentrations over time of ofloxacin and tobramycin in human eyes (Tang-Liu et al). 1994;55:284-92

Omeprazole

Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolic ratios: coincidence with plasma clearance and breath test (Rost and Roots). 1994;55:402-11

Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrate bismuthate (Treiber et al). 1994;55:486-91

Opioids; see Narcotics

P**Paclitaxel**

Paclitaxel (USAN List No. 357). 1994;55:91

Pain

The need for an open mind about the treatment of chronic non-malignant pain (Reidenberg and Portenoy). 1994;55:367-9 (Commentary)

Parenteral nutrition, total

Choline pharmacokinetics during intermittent intravenous choline infusion in human subjects (Buchman et al). 1994;55:277-83

Peptic ulcer

Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrate bismuthate (Treiber et al). 1994;55:486-91

Phenotype

Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways (Carrillo and Benítez). 1994;55:293-304

Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population (May et al). 1994;55:492-500

Phenylpropanolamine

Dispositional factors do not contribute to the enantiospecificity of the cardiovascular effects of phenylpropanolamine (Stockley et al). 1994;55:35-43

Phosphatidylcholines

Choline pharmacokinetics during intermittent intravenous choline infusion in human subjects (Buchman et al). 1994;55:277-83

Pipecuronium bromide

Pipecuronium bromide (USAN List No. 360). 1994;55:607

Pirodavir

Pirodavir (USAN List No. 358). 1994;55:366

Pirsidomine

Pirsidomine (USAN List No. 360). 1994;55:608

Placebos

A placebo-controlled model to assay the onset of action of nonprescription-strength analgesic drugs (Schachtel et al). 1994;55:464-70

Polixetonium chloride

Polixetonium chloride (USAN List No. 357). 1994;55:89

Polymorphism

Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations (Agúndez et al). 1994;55:412-7

Thiopurine methyltransferase activity in American white subjects and black subjects (McLeod et al). 1994;55:15-20

Polymorphism

Polymorphic debrisoquin metabolism in a Turkish population (Bozkurt et al). 1994;55:399-401

Prescriptions, drug

Criteria for judging proposals for national health care reform with respect to therapeutics (Nierenberg and Reidenberg). 1994;55:1-4 (Commentary)

Propafenone

Quinidine-enhanced β -blockade during treatment with propafenone in extensive metabolizer human subjects (Mörke and Roden). 1994;55:28-34

Propranolol

Dose-effect and pharmacokinetic-pharmacodynamic relationships of the β_1 -adrenergic receptor blocking properties of various doses of carvedilol in healthy humans (de Mey et al). 1994;55:329-37

Pharmacokinetic and pharmacodynamic interactions during multiple-dose administration of nisoldipine and propranolol (Shaw-Stiffel et al). 1994;55:661-9

Protein binding

Enhanced covalent binding of tolmetin to proteins in humans after multiple dosing (Zia-Amirhosseini et al). 1994;55:21-7

Protein kinase C

Verapamil decreases lymphocyte protein kinase C activity in humans (DePetrillo et al). 1994;55:44-9

Prothrombin time

Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin (Ermer et al). 1994;55:305-16

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa (Lindley et al). 1994;55:638-48

Q

Quinidine

Quinidine-enhanced β -blockade during treatment with propafenone in extensive metabolizer human subjects (Mörke and Roden). 1994;55:28-34

Quinine

The concentration-effect relationship of quinine-induced hearing impairment (Paintaud et al). 1994;55:317-23

R

Race factors

Thiopurine methyltransferase activity in American white subjects and black subjects (McLeod et al). 1994;55:15-20

Ranitidine

Absence of effect of ranitidine on blood alcohol concentrations when taken morning, midday, or evening with or without food (Toon et al). 1994;55:385-91

Recombinant factor VIIa; see Factor VIIa

Renal failure; see Kidney failure

Reproducibility of results

Effects of intravenous temazepam. II. A study of the long-term reproducibility of pharmacokinetics, pharmacodynamics, and

concentration-effect parameters (van Steveninck et al). 1994;55:546-55

Reviewers

Guest reviewers. 1994;55:477

Rocuronium bromide

Rocuronium bromide (USAN List No. 358). 1994;55:364

S

Saccades

Effects of intravenous temazepam. I. Saccadic eye movements and electroencephalogram after fast and slow infusion to pseudo steady state (van Steveninck et al). 1994;55:535-45

Seasickness; see Motion sickness

Selfotel

Selfotel (USAN List No. 358). 1994;55:364

Sex

Effect of age and gender on tirilazad pharmacokinetics in humans (Hulst et al). 1994;55:378-84

Sibopirdine

Sibopirdine (USAN List No. 361). 1994;55:703

Smoking

Pharmacodynamic effects of cotinine in abstinent cigarette smokers (Keenan et al). 1994;55:581-90

Relationship of electroencephalographic and cardiovascular changes to plasma nicotine levels in tobacco smokers (Kadoya et al). 1994;55:370-7

Smoking cessation

A placebo-controlled study of three clonidine doses for smoking cessation (Gourlay et al). 1994;55:64-9

Sodium

Effect of erythropoietin on renal excretion of a sodium load (Bunke et al). 1994;55:563-8

Sparteine

Single-dose kinetics of clomipramine: relationship to the sparteine and *S*-mephenytoin oxidation polymorphisms (Nielsen et al). 1994;55:518-27

Sulfamethoxazole

Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells: in vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes (Hutabara et al). 1994;55:427-33

T

Tears

Comparative tear concentrations over time of ofloxacin and tobramycin in human eyes (Tang-Liu et al). 1994;55:284-92

Temazepam

Effects of intravenous temazepam. I. Saccadic eye movements and electroencephalogram after fast and slow infusion to pseudo steady state (van Steveninck et al). 1994;55:535-45

Effects of intravenous temazepam. II. A study of the long-term reproducibility of pharmacokinetics, pharmacodynamics, and concentration-effect parameters (van Steveninck et al). 1994;55:546-55

Temocapril hydrochloride

Temocapril hydrochloride (USAN List No. 361). 1994;55:703

Thalassemia

Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous β -thalassemia (Fassos et al). 1994;55:70-5

Thiopurine methyltransferase

Thiopurine methyltransferase activity in American white subjects and black subjects (McLeod et al). 1994;55:15-20

Thromboxane A₂

Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A₂-receptor antagonist AA-2414 in normal subjects: population analysis (Hussein et al). 1994;55:441-50

Tirilazad

Effect of age and gender on tirilazad pharmacokinetics in humans (Hulst et al). 1994;55:378-84

Tobacco; see also Smoking

Relationship of electroencephalographic and cardiovascular changes to plasma nicotine levels in tobacco smokers (Kadoya et al). 1994;55:370-7

Tobramycin

Comparative tear concentrations over time of ofloxacin and tobramycin in human eyes (Tang-Liu et al). 1994;55:284-92

Tolmetin

Enhanced covalent binding of tolmetin to proteins in humans after multiple dosing (Zia-Amirhosseini et al). 1994;55:21-7

Topical administration; see Administration, topical**Total parenteral nutrition; see Parenteral nutrition, total****Tripotassium dicitrato bismuthate**

Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate (Treiber et al). 1994;55:486-91

Truth telling

The Pinocchio factor (Reidenberg). 1994;55:247-8 (Commentary)

U**349U85**

Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects (Clifton et al). 1994;55:55-63

United States Adopted Names Council

Cummulative list for 1993. 1994;55:365-6

USAN Council. 1994;55:89-91, 364-6, 478-80, 606-8, 703-4

Urine

Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in

patients with homozygous β -thalassemia (Fassos et al). 1994;55:70-5

V**Vasodilator agents**

Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects (Clifton et al). 1994;55:55-63

Verapamil

Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics (Schwartz et al). 1994;55:509-17

Verapamil decreases lymphocyte protein kinase C activity in humans (DePetrillo et al). 1994;55:44-9

Vestibule

Cinnarizine in the prophylaxis of seasickness: laboratory vestibular evaluation and sea study (Shupak et al). 1994;55:670-80

W**Warfarin**

Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin (Ermer et al). 1994;55:305-16

Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)-warfarin (including P450 3A4) is not enhanced in cystic fibrosis (Wang et al). 1994;55:528-34

Pharmacodynamic optimization of warfarin therapy (Doi). 1994;55:597-601

Women

Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics (Schwartz et al). 1994;55:509-17

X**Xanthine oxidase**

Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways (Carrillo and Benítez). 1994;55:293-304

